Document is current
Any future updates will be listed below
-
Authors
Hsu, Cynthia L. http://orcid.org/0000-0002-2604-1340
Loomba, Rohit http://orcid.org/0000-0002-4845-9991
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (5P42ES010337)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (5UL1TR001442)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL147835)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (K99AA031328, P50AA011999)
American Association for the Study of Liver Diseases (CTORA23-208366)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
- License Information
-
More Information
Article History
First Online: 21 February 2024
Competing interests
: C.L.H. declares no competing interests. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.
